Detalles de la búsqueda
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697155
2.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
3.
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Breast Cancer Res Treat
; 168(3): 631-638, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29280043
4.
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Breast
; 59: 327-338, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34390999
5.
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
PLoS One
; 9(10): e109611, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25330188
Resultados
1 -
5
de 5
1
Próxima >
>>